Management of antineutrophil cytoplasmic antibody-associated vasculitis: a changing tide

Anoushka Krishnan, Michael Walsh, David Collister

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Purpose of reviewAntineutrophil cytoplasmic antibody associated vasculitis (AAV) is a group of autoimmune disorders of small blood vessels. While outcomes in AAV have improved with the use of glucocorticoids (GC) and other immunosuppressants, these treatments are associated with significant toxicities. Infections are the major cause of mortality within the first year of treatment. There is a move towards newer treatments with better safety profiles. This review reflects on recent advances in the treatment of AAV.Recent findingsThe role of plasma exchange (PLEX) in AAV with kidney involvement has been clarified with new BMJ guideline recommendations following the publication of PEXIVAS and an updated meta-analysis. Lower dose GC regimens are now standard of care. Avacopan (C5a receptor antagonist) was noninferior to a regimen of GC therapy and is a potential steroid-sparing agent. Lastly, rituximab-based regimens were noninferior to cyclophosphamide in two trials for induction of remission and superior to azathioprine in one trial of maintenance of remission.AAV treatments have changed tremendously over the past decade with a drive towards targeted PLEX use, increased rituximab use and lower GC dosing. Striking a crucial balance between morbidity from relapses and toxicities from immunosuppression remains a challenging path to navigate.

Original languageEnglish
Pages (from-to)278-283
Number of pages6
JournalCurrent Opinion in Nephrology and Hypertension
Issue number3
Publication statusPublished - May 2023
Externally publishedYes


Dive into the research topics of 'Management of antineutrophil cytoplasmic antibody-associated vasculitis: a changing tide'. Together they form a unique fingerprint.

Cite this